FDA/Industry Manufacturing Approach Is “Suboptimal” – CDER’s Woodcock
This article was originally published in The Tan Sheet
Executive Summary
FDA is ready to change the current model of manufacturing oversight and enforcement, Center for Drug Evaluation & Research Director Janet Woodcock, MD, indicated during the recent Lehman Brothers Global Healthcare Conference in Orlando
You may also be interested in...
Drug Industry CEOs Are Taking “Positive” Steps On GMPs, FDA’s Galson Says
FDA's discussions with pharmaceutical industry CEOs over the past year give the agency confidence that manufacturing quality is improving, Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, told the Schwab Washington Research Group conference May 2
Drug Industry CEOs Are Taking “Positive” Steps On GMPs, FDA’s Galson Says
FDA's discussions with pharmaceutical industry CEOs over the past year give the agency confidence that manufacturing quality is improving, Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, told the Schwab Washington Research Group conference May 2
Drug Industry CEOs Are Taking “Positive” Steps On GMPs, FDA’s Galson Says
FDA's discussions with pharmaceutical industry CEOs over the past year give the agency confidence that manufacturing quality is improving, Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, told the Schwab Washington Research Group conference May 2